OXALIPLATIN & MODIFIED DE GRAMONT. First-line or subsequent use for metastatic colorectal cancer
|
|
- Iris Hall
- 6 years ago
- Views:
Transcription
1 OXALIPLATIN & MODIFIED DE GRAMONT Indication: For use in patients following resection of stage III / high risk Stage II CRC (to be discussed with consultant) First-line or subsequent use for metastatic colorectal cancer Drugs/ Dosage: Calcium folinate 350mg IV Oxaliplatin 85mg/m 2 IV 5-Fluorouracil 400mg/m 2 IV 5-Fluorouracil 2400mg/m 2 IVI over 46/24 Administration: Frequency: Main Toxicities: Anti-emetics: Oxaliplatin in 250ml 5% Glucose 5% over 2 hours (not using an aluminium needle) concurrently using a Y-line placed immediately before the site of infusion with: Calcium Folinate in 250ml Glucose 5% over 2 hours Flush central venous catheter with Glucose 5%, then: 5FU bolus injection over 5 minutes 5FU infusion either via central venous catheter and ambulatory infusion device or continuous peripheral IV infusion over 46 hours, given in 2 x 1 litre N/Saline. 2 weekly cycle for 12 cycles, CT scan after 6 weeks. myelosuppression; alopecia (usually mild), mucositis; diarrhoea; neurotoxicity (see Comments); hand-foot syndrome (PPE); allergic reactions (see Comments);cardiotoxicity (uncommon);ovarian failure/infertility Highly emetogenic Supportive medication: Extravasation: Calcium gluconate 1g (10ml of 10% solution) and Magnesium sulphate 1g (2ml of 50% solution) in 100ml Glucose 5% over 15-30minutes before and after oxaliplatin chemotherapy. Care in patients with known hypercalcaemia or already treated with thiazides or digoxin. Monitor Ca 2+ and Mg 2+ levels, and omit if above normal. Loperamide tablets 4mg stat, then 2mg prn for diarrhoea Pyridoxine tablets 50mg tds, if required for palmar-plantar erythema (PPE) Non-vesicant Regular investigations: FBC U&Es Mg 2+ Ca 2+ LFTs CEA 4 weekly CT scan after 6 cycles (for metastatic disease) Page 1 of 5
2 Toxicities and Dose Modifications Oxaliplatin and Neurotoxicity Acute Cold-related Dysaesthesia (CRD): Many patients experience transient paraesthesia of hands & feet. Onset is during or within hours of infusion, and resolves within minutes to a few days. Symptoms are exacerbated by cold, so patient should be well advised on precautions to be taken. Does not require treatment or dose reduction. Acute laryngopharyngeal dysaesthesia: Some patients experience laryngopharyngeal dysaesthesia (unpleasant sensations in the throat). Onset is during or within hours of infusion, and resolves within minutes to a few days. Symptoms are exacerbated by cold, so patient should be well advised on precautions to be taken. Does not require treatment or dose reduction. Clinical symptoms Laryngo-pharyngeal dysesthesia Platinum hypersensitivity dyspnoea Present Present bronchospasm Absent Present Laryngospasm Absent Present Anxiety Present Present O2 saturation Normal Decreased Difficulty swallowing Present (loss of sensation) Absent Pruritus Absent Present Cold induced symptoms Yes no Blood pressure Normal or increased Normal or decreased treatment Anxiolytics; observation in a Oxygen, steroids, adrenaline, controlled clinical setting until bronchodilators, antihistamine; symptoms abate or at clinician s Fluids and vasopressors if discretion appropriate Subsequent infusions after episode of laryngo-pharyngeal dysesthesia should be given over 6 hours. Cumulative Dose related peripheral sensory neuropathy Usually occurs after a cumulative dose of 800mg/m 2. It can occur after treatment with oxaliplatin is completed, and is usually reversible, taking approx 3 5 months to recovery. Grade 1 of any duration or grade 2 paraesthesias continue with oxaliplatin 85mg/m 2 lasting longer than 7 days Grade 2 paraesthesias persisting until next cycle reduce oxaliplatin dose to 65mg/m 2 Grade 3 paraesthesias lasting longer than 7 days reduce oxaliplatin dose to 65mg/m 2 Grade 3 paraesthesias persisting until next cycle discontinue oxaliplatin permanently or Grade 4 of any duration discontinue oxaliplatin permanently Page 2 of 5
3 Allergic reactions to oxaliplatin during infusion Immediate intervention is to stop the infusion and call for medical help. Treat with IV corticosteroid and antihistamine. After full recovery, the patient may continue with Folinic Acid and 5FU. At Consultant discretion, the patient may be re-challenged with oxaliplatin on the next cycle, with the following premedication prescribed: Dexamethasone 4mg po 6hrly x 3 doses, starting 24hrs pre-treatment, plus 8mg IV 30 minutes pre dose and Chlorphenamine 10mg IV and Ranitidine 50mg IV 30 minutes pre-dose. Patients who have severe reactions should not be re-challenged, as per SPC. Haematological Toxicity on Neutrophils 1.5 x 10 9 /l and Platelets 75 x 10 9 /l Proceed with treatment, if necessary adjusting doses for any previous haematological toxicity as specified below Neutrophils x 10 9 /l or Platelets x 10 9 /l Delay treatment for 1 week. Repeat FBC and, if recovered, no dose adjustment required. This applies whether this is 1 st, 2 nd or 3 rd occurrence. Neutrophils x 10 9 /l or Platelets x 10 9 /l Delay treatment for 1 week. Repeat FBC and, if recovered, give 75% of original 5FU dose and oxaliplatin 65mg/m 2. If 2 nd occurrence, maintain 5FU dose but reduce oxaliplatin further to 55mg/m 2. Neutrophils < 0.5 x 10 9 /l or Platelets < 10 x 10 9 /l Delay treatment for 1 week. Repeat FBC and, if recovered, give 50% of original 5FU dose and oxaliplatin 55mg/m 2. If any reoccurrence of Grade 4 haematological toxicity, discontinue treatment. If patient suffers an episode of Grade 3 febrile neutropenia, continue after recovery with oxaliplatin 55mg/m 2 and 5FU at 75% of original dose. For Grade 4 neutropenic sepsis or 2 nd occurrence of grade 3, discuss with Consultant. Renal Impairment Before every course, calculate CrCl using Cockcroft and Gault. If borderline, an EDTA should be requested. Creatinine Clearance (ml/min) 5FU Dose Oxaliplatin Dose > 50 Give 100% dose Give 100% dose Give 100% dose Give 100% dose < 30 Give 80% dose Omit Hepatic Impairment Bilirubin > 3 x ULN or ALT/AST > 2.5 ULN Give 50% of 5FU and Oxaliplatin until liver function recovers Page 3 of 5
4 Non-Haematological Toxicities Note that severe diarrhoea and/or severe mucositis early in the first treatment cycle can be the first presenting toxicity due to DPD enzyme deficiency, in which case potentially fatal neutropenia can quickly follow. Toxicity due to 5FU administration may be managed symptomatically and/or modification of the dose. Once the dose has been reduced, it should not be increased at a later time. Doses of 5FU omitted for toxicity are not replaced or restored. Instead the patient should resume the planned treatment cycle. Fluorouracil non-haematological toxicity dosing table: Diarrhoea, abdo pain,n&v,stomatitis Immediate action Dose next cycle Grade 1 maintain dose 100% Grade 2 1 st appearance Interrupt until resolved to grade % Grade 2 2 nd appearance Interrupt until resolved to grade % Grade 2 3 rd appearance Interrupt until resolved to grade % Grade 2 4 th appearance Discontinue treatment permanently Grade 3 1 st appearance Interrupt until resolved to grade % Grade 3 2 nd appearance Interrupt until resolved to grade % Grade 3 3 rd appearance Discontinue treatment permanently Grade 4 1 st appearance Discontinue or at consultants discretion Interrupt until resolved to grade % Palmar-Plantar Erythema Immediate action Dose next cycle Grade 1 maintain dose 100% Grade 2 1 st appearance Interrupt until resolved to grade % Grade 2 2 nd appearance Interrupt until resolved to grade % Grade 2 3 rd appearance Discontinue treatment permanently Grade 3 1 st appearance Interrupt until resolved to grade % Grade 3 2 nd appearance Discontinue or at consultants discretion Interrupt until resolved to grade % In Grade 3 or 4 stomatitis or diarrhoea reduce Oxaliplatin dose to 65mg/m 2. Other Toxicities Oxaliplatin therapy should be interrupted if symptoms indicative of pulmonary fibrosis develop nonproductive cough, dyspnea, crackles, rales, hypoxia, tachypnea or radiological pulmonary infiltrates. If pulmonary fibrosis is confirmed oxaliplatin should be discontinued. Venous Occlusive Disease is a rare but serious complications that has been reported in patients (0.02%) receiving Oxaliplatin in combination with Fluorouracil. This condition can lead to hepatomegaly, splenomegaly, portal Page 4 of 5
5 hypertension and/or esophageal varices. Patients should be instructed to report any jaundice, ascites or hematemesis immediately. Oxaliplatin therapy should be interrupted if Hemolytic Uremic Syndrome (HUS) is suspected: hematocrit is <25%, platelets<100,000 and creatinine > 135 umol/l. If HUS is confirmed, Oxaliplatin should be permanently discontinued Cardiotoxicity Coronary artery spasm is a recognised complication of fluoropyrimidines although the evidence base regarding aetiology, management & prognosis is not particularly strong. The incidence is estimated to be between 2% and 18%. Coronary artery spasm is usually reversible on discontinuing the treatment. Should a patient receiving 5FU present with chest pains, stop the treatment. Standard investigation and treatment of angina may be required. If re-challenge is deemed necessary, this can be performed under close supervision, but should symptoms redevelop, 5FU should be withdrawn permanently. Refer to Consultant to discuss. Neurotoxicity Drug interactions: Caution must be exercised in patients with central or peripheral nervous system disease e.g. cerebral metastasis or neuropathy Coumarin anticoagulants-monitor INR Phenytoin- altered plasma levels Aminoglycoside anticiotics- increased risk of ototoxicity with oxaliplatin Metronidazole- increased plasma levels and toxicity Folinic acid- increased toxicity Allopurinol- reduced efficacy Antacids- absorption interference References: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.andre et al., NEJM 2004; 350: Leucovorin and fluorouracil with or without Oxaliplatinas first-line Treatment in Advanced Colorectal Cancer. De Gramont et al, JCO 2000; 18: Modified de Gramont with oxaliplatin in the first-line treatment of advanced colorectal cancer.braun et al., BJC 2003; 89 (7): Gamelin et al; Clinical Cancer Research 2004; 10; GI ASCO, abstract 280. CONCEPT trial. Summerhayes et al. Practical chemotherapy Royal Surrey County Hospital chemotherapy protocols Summary of Product Characteristics- Fluorouracil, Wockhardt. Revised Sept 2006 Summary of Product Characteristics-Oxaliplatin. Sanofi-Aventis. Revised Aug 2007 Micromedex review, Fluorouracil. Sept2007 BCCA Protocol summary. UGIAJFFOX. Revised July 2007 Page 5 of 5
EOX. Advanced / metastatic use: 8 cycles (CT scan after cycles 4 and 8)
EOX Page 1 of 6 As an alternative to ECX: For locally advanced (inoperable) or metastatic oesophageal or gastric cancer For patients able to take oral medications Drugs/Dosage: Epirubicin 50mg/m 2 IV D1
More informationOxaliplatin, Irinotecan & Fluorouracil (FOLFOXIRI) for metastatic colorectal carcinoma
Oxaliplatin, Irinotecan & Fluorouracil (FOLFOXIRI) for metastatic colorectal carcinoma Indication: Unresectable metastatic adenocarcinoma of the colon or rectum. First-line or subsequent use following
More informationECX. Anti-emetics: Day 1: highly emetogenic Days 2 21: mildly emetogenic
Page 1 of 5 As an alternative to ECF: For locally advanced (inoperable) or metastatic oesophageal or gastric cancer; peri-operative use in oesophageal or gastric cancer; adenocarcinoma of unknown primary
More informationFOLFIRINOX (pancreas)
FOLFIRINOX (pancreas) Indication First or second line chemotherapy for metastatic pancreatic cancer. Eligible patients must be
More informationFluorouracil, Oxaliplatin and Docetaxel (FLOT)
Fluorouracil, Oxaliplatin and Docetaxel (FLOT) Indication Perioperative chemotherapy for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma. ICD-10 codes Codes with a prefix C15,C16 Regimen
More informationCapecitabine Oxaliplatin 21 day cycle (XELOX)
Systemic Anti Cancer Treatment Protocol Capecitabine Oxaliplatin 21 day cycle (XELOX) PROTOCOL REF: MPHAXELOX (Version No: 1.0) Approved for use in: Adjuvant colorectal cancer stage 3 or high risk stage
More informationCapecitabine Oxaliplatin 21 day cycle (CAPOX)
Systemic Anti Cancer Treatment Protocol Oxaliplatin 21 day cycle (CAPOX) PROTOCOL REF: MPHACAPOX (Version No: 1.0) Approved for use in: Adjuvant colorectal cancer stage 3 or high risk stage 2 Advanced
More informationCisplatin / Capecitabine (+ Trastuzumab) in Gastric Cancer
Cisplatin / Capecitabine (+ Trastuzumab) in Gastric Cancer Page 1 of 5 Indication: Confirmed HER2-positive (3+ or FISH+) metastatic adenocarcinoma of the stomach or gastrooesophageal junction. Patient
More informationNCCP Chemotherapy Regimen. FOLFOX-4 Therapy-14 day
INDICATIONS FOR USE: FOLFOX-4 Therapy-14 day INDICATION ICD10 Regimen Code Adjuvant treatment of stage II or III colon cancer after C18 00210a complete resection of primary tumour Metastatic colorectal
More informationNCCP Chemotherapy Regimen. Modified FOLFOX-6 Therapy-14 day
INDICATIONS FOR USE: Modified FOLFOX-6 Therapy-14 day INDICATION ICD10 Regimen Code Adjuvant treatment of stage II or III colon cancer after C18 00209a complete resection of primary tumour Metastatic colorectal
More informationCisplatin / 5-Fluorouracil for Vulval Cancer
Cisplatin / 5-Fluorouracil for Vulval Cancer Indication: Palliative therapy in patients with Vulval Cancer Regimen details: Cisplatin 75mg/m 2 (*) IV 5-Fluorouracil (5-FU) 1000mg/m 2 /24 hours IV D4 (*)Consider
More informationOxaliplatin and Gemcitabine
Oxaliplatin and Gemcitabine Indication Palliative treatment for relapsed metastatic seminoma, non seminoma or combined tumours. ICD-10 codes Codes pre-fixed with C38, C48, C56, C62, C63, C75.3. Regimen
More informationFOLFIRINOX (Irinotecan, Oxaliplatin & infusional Fluorouracil) Cumbria, Northumberland, Tyne & Wear Area Team
DRUG ADMINISTRATION SCHEDULE Day Drug Dose Route Diluent & Rate Glucose 5% 250ml Infusion Fast Running for Line Flush Day 1 Ondansetron 8mg IV bolus Via dextrose drip Dexamethasone 8mg IV bolus Via dextrose
More informationDrug Dose BC Cancer Administration Guidelines oxaliplatin 130 mg/m 2 IV in 500 ml* of D5W over 2 hours capecitabine 1000 mg/m 2 BID PO x 14 days
BC Cancer Protocol Summary for Adjuvant Chemotherapy of Gastric Cancer Patients with D2 Resection (node negative) or Ineligible for Adjuvant Chemoradiation Using Oxaliplatin and Capecitabine Protocol Code:
More informationBC Cancer Protocol Summary for Adjuvant Combination Chemotherapy for Stage III and Stage IIB Colon Cancer Using Oxaliplatin and Capecitabine
BC Cancer Protocol Summary for Adjuvant Combination Chemotherapy for Stage III and Stage IIB Colon Cancer Using Oxaliplatin and Capecitabine Protocol Code: Tumour Group: Contact Physician: GIAJCAPOX Gastrointestinal
More informationLung Pathway Group Docetaxel & Carboplatin in Non- Small Cell Lung Cancer (NSCLC)
Lung Pathway Group Docetaxel & Carboplatin in Non- Small Cell Lung Cancer (NSCLC) Indication: First line palliative therapy for previously untreated Stage IIIB or IV NSCLC patients Regimen details: Docetaxel
More informationCisplatin / 5-Fluorouracil (+ Trastuzumab) in Gastric Cancer
Cisplatin / 5-Fluorouracil (+ Trastuzumab) in Gastric Cancer Indication: Confirmed HER2-positive (3+ or FISH+) metastatic adenocarcinoma of the stomach or gastro-oesophageal junction. For Trastuzumab doses
More informationNCCP Chemotherapy Regimen. Modified FOLFOX-6 Therapy-14 day
INDICATIONS FOR USE: Modified FOLFOX-6 Therapy-14 day INDICATION ICD10 Regimen Code *Reimbursement Status Adjuvant treatment of stage II or III colon cancer after C18 00209a Hospital complete resection
More informationCapecitabine and Oxaliplatin Therapy (XELOX)
INDICATIONS FOR USE: and Therapy (XELOX) Regimen Code *Reimbursement Status INDICATION ICD10 Adjuvant treatment of stage III (Dukes C) C18 00321a CDS colon cancer after complete resection of Hospital the
More informationBCCA Protocol Summary for Palliative Combination Chemotherapy for Metastatic Colorectal Cancer Using Oxaliplatin, and Capecitabine
BCCA Protocol Summary for Palliative Combination Chemotherapy for Metastatic Colorectal Cancer Using Oxaliplatin, and Capecitabine Protocol Code: Tumour Group: Contact Physician: GICAPOX Gastrointestinal
More informationIrinotecan Capecitabine (14 day regimen) (I-Cap)
Systemic Anti Cancer Treatment Protocol Irinotecan (14 day regimen) (I-Cap) PROTOCOL REF: MPHAICAP (Version No: 1.0) Approved for use in: Advanced colorectal cancer first line Advanced colorectal cancer
More informationCarboplatin + Paclitaxel Cancer of the Cervix
Carboplatin + Paclitaxel Cancer of the Cervix Background: Topotecan in combination with cisplatin is recommended as a treatment option for women with recurrent or stage IVB cervical cancer only if they
More informationLung Pathway Group Carboplatin & PO Vinorelbine in Non-Small Cell Lung Cancer (NSCLC)
Lung Pathway Group Carboplatin & PO Vinorelbine in Non-Small Cell Lung Cancer (NSCLC) Indication: First line in radical/induction treatment in locally advanced NSCLC First line palliative treatment in
More informationMCF: Mitomycin C / Cisplatin / PVI Fluorouracil for Advanced Oesophageal or Gastric Cancer
MCF: Mitomycin C / Cisplatin / PVI Fluorouracil for Advanced Oesophageal or Gastric Cancer Indication: Second line palliative therapy for locally advanced or Metastatic Oesophageal or Gastric Cancer, especially
More informationCarboplatin and Fluorouracil
Carboplatin and Fluorouracil Indication Palliative chemotherapy for recurrent or metastatic head and neck squamous cell cancer for patients where cisplatin and / or cetuximab are not appropriate. Performance
More informationCisplatin / 5-Fluorouracil for Neoadjuvant Oesophageal Cancer
Cisplatin / 5-Fluorouracil for Neoadjuvant Oesophageal Cancer Indication: Neoadjuvant therapy for resectable Oesophageal Cancer Regimen details: Cisplatin 80mg/m 2 IV 5-Fluorouracil (5-FU) 1000mg/m 2 /24
More informationBreast Pathway Group EC x 4 Docetaxel x 4: Epirubicin & Cyclophosphamide followed by Docetaxel in Early Breast Cancer
Breast Pathway Group EC x 4 Docetaxel x 4: Epirubicin & Cyclophosphamide followed by Docetaxel in Early Breast Indication: Neoadjuvant therapy for high risk and fit breast cancer patients suitable for
More informationTESTS AND MONITORING:
BC Cancer Protocol Summary for Combined Modality Therapy for Locally Advanced Esophageal Cancer using Oxaliplatin, Fluorouracil, Leucovorin, and Radiation Therapy Protocol Code: GIEFFOXRT Tumour Group:
More information2 weekly Cetuximab in combination with OxMdG Chemotherapy 1 st line Metastatic Colorectal Cancer
Cetuximab in Combination with Oxaliplatin Modified DeGramont for the 1 st line treatment of Metastatic Colorectal Cancer DRUG ADMINISTRATION SCHEDULE Day Drug Daily Dose Route Diluent and rate Day 1 Cetuximab
More informationLung Pathway Group Cisplatin & IV Vinorelbine in Non- Small Cell Lung Cancer (NSCLC)
Lung Pathway Group Cisplatin & IV Vinorelbine in Non- Small Cell Lung Cancer (NSCLC) Indication: First line in radical/induction treatment in locally advanced NSCLC First line palliative treatment in advanced/metastatic
More informationLung Pathway Group Cisplatin & PO Vinorelbine in Non- Small Cell Lung Cancer (NSCLC)
Lung Pathway Group Cisplatin & PO Vinorelbine in Non- Small Cell Lung Cancer (NSCLC) Indication: First line in radical/induction treatment in locally advanced NSCLC First line palliative treatment in advanced/metastatic
More informationLapatinib and capecitabine for breast cancer Funding arrangements to be set up and specified locally Page 1 of 5
Indication: Funding arrangements to be set up and specified locally Page 1 of 5 Lapatinib in combination with Capecitabine is recommended as a treatment option for people with advanced and/or metastatic
More informationNECN CHEMOTHERAPY HANDBOOK PROTOCOL
DRUG ADMINISTRATION SCHEDULE First Cycle: Day Drug Daily Dose Route Diluent & Rate 1 Chlorphenamine 10mg IV bolus 1 Paracetamol 1000mg ORAL 1 Ranitidine 150mg ORAL 1 Dexamethasone 8mg IV bolus 1 Cetuximab
More informationNECN CHEMOTHERAPY HANDBOOK PROTOCOL
DRUG ADMINISTRATION SCHEDULE First Cycle: Day Drug Daily Dose Route Diluent & Rate 1 Chlorphenamine 10mg IV bolus 1 Paracetamol 1000mg ORAL 1 Ranitidine 150mg ORAL 1 Dexamethasone 8mg IV bolus 1 Cetuximab
More informationBreast Pathway Group Epirubicin & Cyclophosphamide x 4 followed by Carboplatin & Paclitaxel x 4 for Early Breast Cancer
Breast Pathway Group Epirubicin & Cyclophosphamide x 4 followed by Carboplatin & Paclitaxel x 4 for Early Breast Cancer Indication: Neoadjuvant therapy for patients with BRCA1/2 mutations EC Regimen details:
More informationCapecitabine plus Docetaxel in Advanced Breast Cancer
Capecitabine plus Docetaxel in Advanced Breast Cancer Indication: Palliative therapy in Anthracycline-Pretreated Patients with Advanced Breast Cancer Regimen details: Docetaxel 75mg/m 2 IV D1 Capecitabine*
More informationNCCP Chemotherapy Regimen. Bevacizumab 5mg/kg and Modified FOLFOX- 6 Therapy 14 days
Bevacizumab 5mg/kg and Modified FOLFOX- 6 Therapy 14 days INDICATIONS FOR USE: Regimen Code 00446a *Reimbursement Indicator INDICATION ICD10 Treatment of adult patients with metastatic carcinoma of the
More informationCAPECITABINE (METASTATIC BREAST CANCER) (BRWOS-002/1)
West of Scotland Cancer Network Chemotherapy Protocol Indication CAPECITABINE (METASTATIC BREAST CANCER) (BRWOS-002/1) Capecitabine (Xeloda) monotherapy is indicated for the treatment of locally advanced
More informationCisplatin + Etoposide IV / Oral therapy followed by Chemo-radiotherapy in Small Cell Carcinoma of the Cervix
Cisplatin + Etoposide IV / Oral therapy followed by Chemo-radiotherapy in Small Cell Carcinoma of the Cervix Indication: Neoadjuvant chemotherapy followed by Chemo-radiotherapy in Small Cell Carcinoma
More informationBreast Pathway Group EC x 4 Paclitaxel x 4 (3-weekly): Epirubicin & Cyclophosphamide x 4 followed by Paclitaxel x 4 (3-weekly) in Early Breast Cancer
Breast Pathway Group EC x 4 Paclitaxel x 4 (3-weekly): Epirubicin & Cyclophosphamide x 4 followed by Paclitaxel x Indication: Neoadjuvant or adjuvant therapy for moderate to high risk node positive breast
More informationECF: Epirubicin / Cisplatin / PVI 5-Fluorouracil for Locally Advanced and Metastatic Non Squamous Cell Carcinoma Head and Neck
ECF: Epirubicin / Cisplatin / PVI 5-Fluorouracil for Locally Advanced and Metastatic Non Squamous Cell Carcinoma Head and Neck Indication: Palliative therapy for Locally Advanced and Metastatic : - Adenocarcinoma
More informationFEC-T (Fluorouracil, Epirubicin and Cyclophosphamide and Docetaxel)
FEC-T (Fluorouracil, Epirubicin and Cyclophosphamide and Docetaxel) Indication Adjuvant or neo-adjuvant treatment for high risk early and locally advanced breast cancer. (NICE CG80) ICD-10 codes Codes
More informationNCCP Chemotherapy Regimen. Modified FOLFIRINOX Therapy
INDICATIONS FOR USE: Modified FOLFIRINOX Therapy Regimen *Reimbursement INDICATION ICD10 Code Status Adjuvant treatment of pancreatic ductal adenocarcinoma C25 00515a Hospital *If the reimbursement status
More informationBEVACIZUMAB (AVASTIN ) AND XELOX PROTOCOL
Bevacizumab (Avastin ) for the first line treatment of advanced colorectal cancer with XELOX DRUG ADMINISTRATION Day Drug Daily Dose Route Diluent & Rate Day 1 Bevacizumab 7.5mg/kg Infusion Day 1 Days
More informationPanitumumab + FOLFOX for the 1 st line Treatment of Metastatic Colorectal Cancer
DRUG ADMINISTRATION SCHEDULE Day Drug Daily Dose Route Diluent and rate Day 1 Panitumumab 6mg/kg Intravenous 100ml Sodium Chloride 0.9% at variable rate (see administration notes) Glucose 5% 500ml Infusion
More informationBreast Pathway Group Docetaxel in Advanced Breast Cancer
Breast Pathway Group Docetaxel in Advanced Breast Cancer Indication: First-line palliative treatment, with or without trastuzumab, for advanced breast cancer in patients for whom an anthracycline is not
More informationCisplatin Vinorelbine (Oral) therapy +/- radiotherapy
1 REGIMEN TITLE: Cisplatin Vinorelbine (Oral) therapy +/- radiotherapy Page 1 of 5 Indication: First line in Radical/ Induction, Adjuvant and Advanced & Palliative treatment of Non-small cell lung cancer
More informationCisplatin/ 5-Fluorouracil for Squamous Cell Carcinoma Head and Neck (HNSCC) Day unit protocol
Cisplatin/ 5-Fluorouracil for Squamous Cell Carcinoma Head and Neck (HNSCC) Day unit protocol Indication: 1) Neoadjuvant: Non-resectable and/or locally advanced Squamous Cell Carcinoma Head and Neck/ Nasopharyngeal
More informationR-GemOx. Lymphoma group INDICATION. Relapsed or Refractory Lymphoma, for patients unsuitable for R-GDP regimen. Omit rituximab if CD20- negative
R-GemOx INDICATION Relapsed or Refractory Lymphoma, for patients unsuitable for R-GDP regimen. Omit rituximab if CD20- negative TREATMENT INTENT Disease modification PRE-ASSESSMENT 1. Ensure histology
More informationBreast Pathway Group FEC75 (Fluorouracil / Epirubicin / Cyclophosphamide) in Early Breast Cancer
Breast Pathway Group FEC75 (Fluorouracil / Epirubicin / Cyclophosphamide) in Early Breast Cancer Indication: Neoadjuvant or adjuvant therapy in early breast cancer Regimen details: Fluorouracil 600mg/m
More informationBreast Pathway Group TC (Docetaxel / Cyclophosphamide) in Early Breast Cancer
Breast Pathway Group TC (Docetaxel / Cyclophosphamide) in Early Breast Cancer Indication: Neoadjuvant or adjuvant treatment for patients in whom anthracyclines are contraindicated or inappropriate Regimen
More informationModified De Gramont with Oxaliplatin(OxMdg) Metastatic colorectal cancer (GIWOS-002) CONSIDER ENTRY INTO CLINICAL TRIAL IF AVAILABLE/APPROPRIATE
West of Scotland Cancer Network Chemotherapy Protocol Modified De Gramont with Oxaliplatin(OxMdg) Metastatic colorectal cancer (GIWOS-002) Indication Metastatic colorectal cancer Case selection Inclusion
More informationWoSCAN CP Xelox Met CR version 2.0 October 2007 Page 1 of 10
West of Scotland Cancer Network Chemotherapy Protocol Oxaliplatin plus Capecitabine (XELOX) Metastatic Colorectal Cancer (GIWOS-004/2) Indication First line therapy of metastatic colorectal cancer Case
More informationCisplatin and Fluorouracil (head and neck)
Cisplatin and Fluorouracil (head and neck) Indication Palliative chemotherapy for recurrent or metastatic head and neck squamous cell cancer where combination treatment with cetuximab is not indicated.
More informationDocetaxel-EC: Docetaxel followed by Epirubicin / Cyclophosphamide in Breast Cancer
Docetaxel-EC: Docetaxel followed by Epirubicin / Cyclophosphamide in Breast Cancer Indication: Neoadjuvant therapy f HER 2 negative high risk and fit Breast Cancer patients, suitable f a taxane containing
More informationCisplatin and Fluorouracil
Cisplatin and Fluorouracil Indication Neo-adjuvant treatment of nasopharyngeal head and neck cancer (stage II-IV) or bulky disease at other head and neck sites. Performance Status 0-1 ICD-10 codes Codes
More informationNCCP Chemotherapy Regimen
QUASAR (Modified) Fluorouracil (370mg/m 2 ) and Folinic Acid (50mg) Weekly INDICATIONS FOR USE: Regimen INDICATION ICD10 Code Treatment of metastatic colorectal cancer C18 00428a Adjuvant treatment of
More informationOxaliplatin, 5-Fluorouracil & Folinic Acid (OxMdG) plus Panitumumab
Oxaliplatin, 5-Fluorouracil & Folinic Acid (OxMdG) plus Panitumumab Available for Routine Use in Not routinely commissioned, each case requires prior documented approval before offering & commencing therapy
More informationNCCP Chemotherapy Regimen
Modified Roswell Park (Fluorouracil 500mg/m 2 and Folinic Acid 50mg weekly x 6) Regimen INDICATIONS FOR USE: Regimen INDICATION ICD10 Code Treatment of metastatic colorectal cancer C18 00427a Adjuvant
More informationCarboplatin / Gemcitabine Gynaecological Cancer
Systemic Anti Cancer Treatment Protocol Carboplatin / Gemcitabine Gynaecological Cancer PROCTOCOL REF: MPHAGYNCAG (Version No: 1.0) Approved for use in: Recurrent/metastatic endometrial carcinoma Previously
More informationCisplatin and Fluorouracil (palliative)
Cisplatin and Fluorouracil (palliative) Indication Palliative chemotherapy for recurrent or metastatic head and neck squamous cell cancer where combination treatment with cetuximab is not indicated. PS0-1
More informationNCCP Chemotherapy Regimen. FLOT Therapy-14 day
INDICATIONS FOR USE: FLOT Therapy-14 Regimen Code 00344a *Reimbursement Indicator INDICATION ICD10 Treatment of locally advanced ( T2) and/or nodal positive (N+) C16 resectable gastric adenocarcinoma Treatment
More informationThames Valley Thames Valley Chemotherapy Regimens Colorectal Cancer
Chemotherapy Regimens Colorectal Cancer Chemotherapy Regimens Colorectal Cancer 1 Notes from the editor These regimens are available on the Network website www.tvscn.nhs.uk. Any correspondence about the
More informationThames Valley Thames Valley Chemotherapy Regimens Colorectal Cancer
Chemotherapy Regimens Colorectal Cancer Chemotherapy Regimens Colorectal Cancer 1 Notes from the editor All chemotherapy regimens, and associated guidelines eg antiemetics and dose bands are available
More informationFEC Docetaxel (NEOADJUVANT): Fluorouracil/ Epirubicin/ Cyclophosphamide followed by Docetaxel* in Early Breast Cancer
FEC Docetaxel (NEOADJUVANT): Fluouracil/ Epirubicin/ Cyclophosphamide followed by Docetaxel* in Early Breast Cancer Please, note that Neoadjuvant FEC-Docetaxel has only been approved f use in QEW Trust
More informationBreast Pathway Group EC x 4: Epirubicin & Cyclophosphamide in Early Breast Cancer
Breast Pathway Group EC x 4: & in Early Breast Cancer Indication: Neoadjuvant or adjuvant treatment for moderate to high risk breast cancer Regimen details: 90 mg/m 2 IV Day 1 600 mg/m 2 IV Day 1 Administration:
More informationEC-Docetaxel: Epirubicin / Cyclophosphamide followed by Docetaxel in Breast Cancer
EC-Docetaxel: Epirubicin / Cyclophosphamide followed by Docetaxel in Breast Cancer Indication: Neoadjuvant therapy f high risk and fit Breast Cancer patients, suitable f a taxane containing regimen EC
More informationCarboplatin, Paclitaxel and Bevacizumab (gynae)
Carboplatin, Paclitaxel and Bevacizumab (gynae) Indication First line treatment of recurrent or metastatic cervical cancer. WHO performance status 0 or 1. First line treatment of advanced epithelial ovarian,
More informationE 90 C followed by Weekly Paclitaxel
E 90 C followed by Weekly Paclitaxel Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community Burton out-patient Derby out-patient
More informationCisplatin and Vinorelbine and radiotherapy (NSCLC)
Cisplatin and Vinorelbine and radiotherapy (NSCLC) Indication First-line chemotherapy for use with concomitant radical radiotherapy for early or locally advanced non-small cell carcinoma (NSCLC) ICD-10
More informationTCHP Docetaxel, Carboplatin, Trastuzumab, Pertuzumab Neoadjuvant Protocol
Systemic Anti Cancer Treatment Protocol TCHP Docetaxel, Carboplatin, Trastuzumab, Pertuzumab Neoadjuvant Protocol PROTOCOL REF: MPHATCHP (Version No: 1.0) Approved for use in: Neoadjuvant breast: The neoadjuvant
More informationOxaliplatin plus Capecitabine (XELOX) Adjuvant Colorectal Cancer (GIWOS-007)
West of Scotland Cancer Network Chemotherapy Protocol Indication Oxaliplatin plus Capecitabine (XELOX) Adjuvant Colorectal Cancer (GIWOS-007) 1. Duke s C colon cancer patients 2. Duke s C rectal cancer
More informationGemcitabine + Capecitabine (ESPAC-4 Trial)
Gemcitabine + Capecitabine (ESPAC-4 Trial) European Study Group For Pancreatic Cancer - Trial 4. Combination versus single agent chemotherapy in resectable pancreatic ductal and ampullary cancers. ***
More informationCisplatin and Vinorelbine and radiotherapy (NSCLC)
Cisplatin and Vinorelbine and radiotherapy (NSCLC) Indication First-line chemotherapy for use with concomitant radical radiotherapy for early or locally advanced non-small cell carcinoma (NSCLC) ICD-10
More informationEpirubicin, Cisplatin and Capecitabine (ECX) - Metastatic Gastric cancer (GIWOS-101/1)
West of Scotland Cancer Network Chemotherapy Protocol Indication Epirubicin, Cisplatin and Capecitabine (ECX) - Metastatic Gastric cancer (GIWOS-101/1) Patients with inoperable gastric or oesophago-gastric
More informationBreast Pathway Group Bevacizumab & Paclitaxel in Advanced Breast Cancer
Breast Pathway Group Bevacizumab & Paclitaxel in Advanced Breast Cancer Indication: First-line or second-line treatment of triple negative advanced breast cancer National Cancer Drug Fund criteria: Advanced
More informationBreast Pathway Group Gemcitabine & Paclitaxel in Advanced Breast Cancer
Breast Pathway Group Gemcitabine & Paclitaxel in Advanced Breast Cancer Indication: Alternative palliative treatment for advanced breast cancer in patients where docetaxel monotherapy or docetaxel/capecitabine
More informationNCCP Chemotherapy Regimen. Epirubicin, Oxaliplatin and Capecitabine (EOX) -21 day
INDICATIONS FOR USE: Epirubicin, Oxaliplatin and Capecitabine (EOX) -21 day Regimen INDICATION ICD10 Code Locally advanced or metastatic gastric carcinoma C16 00239a Locally advanced or metastatic oesophageal
More informationBevacizumab + Paclitaxel & Carboplatin
Bevacizumab + Paclitaxel & Carboplatin Available for Routine Use in Not routinely commissioned, each case requires prior documented approval before offering & commencing therapy from NHS England Cancer
More informationCISPLATIN Chemo-radiation regimen Gynaecological Cancer
Systemic Anti Cancer Treatment Protocol CISPLATIN Chemo-radiation regimen Gynaecological Cancer PROCTOCOL REF: MPHAGYNCIX (Version No: 1.0) Approved for use in: Locally advanced cervical cancer (adjuvant/curative)
More informationX M/ (R) Dose adjusted (DA)-EPOCH-R
X M/ (R) adjusted (DA)-EPOCH-R Indication High-risk CD20+ diffuse large B cell lymphoma especially C-MYC and BCL-2 activated (i.e. double hit lymphoma) and mediastinal sclerosing (thymic) large B cell
More informationPaclitaxel Gynaecological Cancer
Systemic Anti Cancer Treatment Protocol Paclitaxel Gynaecological Cancer PROTOCOL REF: MPHAGYNPAC (Version No: 1.0) Approved for use in: Second/ third line option for advanced ovarian cancers (3 weekly
More informationCapecitabine + Concurrent Radiotherapy
Capecitabine + Concurrent Radiotherapy Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community Burton out-patient Derby out-patient
More informationCarboplatin / Liposomal Doxorubicin CARBO/CAELYX Gynaecological Cancer
Systemic Anti Cancer Treatment Protocol Carboplatin / CARBO/CAELYX Gynaecological Cancer PROCTOCOL REF: MPHAGYNCCX (Version No: 1.0) Approved for use in: Advanced ovarian cancer in women who have progressed
More informationCisplatin / Paclitaxel Gynaecological Cancer
Systemic Anti Cancer Treatment Protocol Cisplatin / Paclitaxel Gynaecological Cancer PROCTOCOL REF: MPHAGYNCIP (Version No: 1.0) Approved for use in: First line treatment for stage Ib-IV with minimal residual
More informationSunitinib (renal) ICD-10 codes Codes with a prefix C64
Sunitinib (renal) Indication First line treatment of patients with advanced and/or metastatic renal cell carcinoma who are suitable for immunotherapy and have an Eastern Cooperative Oncology Group (ECOG)
More informationHerceptin (Trastuzumab) plus Capecitabine & Cisplatin (HCX)
Herceptin (Trastuzumab) plus Capecitabine & Cisplatin (HCX) DRUG ADMINISTRATION SCHEDULE First Cycle Only: Day Drug Daily Dose Route Diluent and Rate 1 to 21 Capecitabine 625mg/m 2 Day 1 TWICE DAILY Oral
More information5-FU & Cisplatin + Cetuximab
5-FU & Cisplatin + Cetuximab Available for Routine Use in Not routinely commissioned, each case requires prior documented approval before offering & commencing therapy from either: a) the relevant PCT
More informationCisplatin and Gemcitabine (bladder)
Cisplatin and Gemcitabine (bladder) Indication Palliative therapy for locally advanced or metastatic bladder cancer in patients with good renal function. Palliative therapy for urothelial transitional
More informationCetuximab in Combination with Irinotecan based Chemotherapy for the 1 st, 2 nd and 3 rd treatment Metastatic of Colorectal Cancer
Cetuximab in Combination with Irinotecan based Chemotherapy for the 1 st, 2 nd and 3 rd treatment Metastatic of Colorectal Cancer DRUG ADMINISTRATION SCHEDULE Day Drug Daily Dose Route Diluent and rate
More informationNCCP Chemotherapy Regimen
INDICATIONS FOR USE: Capecitabine Monotherapy Regimen *Reimbursement INDICATION ICD10 Code Indicator Treatment of patients with locally advanced or metastatic breast cancer C50 00216a CDS Treatment of
More informationTESTS AND MONITORING:
BC Cancer Protocol Summary for Palliative Combination Chemotherapy for Advanced Pancreatic Adenocarcinoma Using Irinotecan, Oxaliplatin, Fluorouracil and Leucovorin Protocol Code: Tumour Group: Contact
More informationCisplatin and Pemetrexed (NSCLC, mesothelioma)
Cisplatin and Pemetrexed (NSCLC, mesothelioma) Indication First-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) if the histology of the tumour has been confirmed as
More informationCisplatin100 plus Radiotherapy for locally Advanced Squamous Cell Carcinoma Head and Neck
Cisplatin100 plus Radiotherapy for locally Advanced Squamous Cell Carcinoma Head and Neck Indication: 1) Concomitant chemo-radiotherapy for locally advanced squamous cell carcinoma head and neck 2) Post-operative
More informationThames Valley. Thames Valley Chemotherapy Regimens Upper Gastrointestinal Cancer
Chemotherapy Regimens Upper Gastrointestinal Cancer Notes from the editor These regimens are available on the Network website www.tvscn.nhs.uk. Any correspondence about the regimens should be addressed
More informationCarboplatin and Paclitaxel (gynae)
Carboplatin and Paclitaxel (gynae) Indication Post surgical adjuvant or neoadjuvant or relapse therapy for stage IC to IV ovarian, fallopian tube or primary peritoneal cancer. First line or relapse therapy
More informationPanitumumab + FOLFIRI for the 1 st line Treatment of Metastatic Colorectal Cancer
DRUG ADMINISTRATION SCHEDULE Day Drug Daily Dose Route Diluent and rate Day 1 Panitumumab 6mg/kg Intravenous 100ml Sodium Chloride 0.9% at variable rate (see administration notes) Glucose 5% 500ml Infusion
More informationGemcitabine, Carboplatin and Bevacizumab (gynae)
Gemcitabine, Carboplatin and Bevacizumab (gynae) Indication Second line advanced epithelial ovarian, fallopian tube or primary peritoneal cancer. WHO performance status 0 or 1. (Funding via the CDF) ICD-10
More informationBCCA Protocol Summary for Adjuvant Therapy of Colon Cancer using
BCCA Protocol Summary for Adjuvant Therapy of Colon Cancer using Capecitabine Protocol Code Tumour Group Contact Physician GIAJCAP Gastrointestinal GI Systemic Therapy ELIGIBILITY: Resected Stage III or
More informationBreast Pathway Group Oral Vinorelbine 3 weekly cycle in Advanced Breast Cancer
Breast Pathway Group Oral Vinorelbine 3 weekly cycle in Advanced Breast Cancer Indication: Regimen details: Administration: Frequency: Pre-medication: Anti- emetics: Supportive medication: Extravasation:
More information